Following the introduction of targeted agents beginning in the late 1990s, there is a common misconception that the use of older cancer therapies, such as radiation, is on the decline.
Earthquake Highlights Unmet Need for Treating Radiation Sickness
March 13, 2011 By 4 Comments
Few treatment options exist for exposure to high doses of ionizing radiation over a short period of time, which would be expected following the meltdown of a nuclear reactor and other scenarios.
FDA Advisory Panels: No Means No, Yes Means Maybe
February 6, 2011 By 4 Comments
As the only company to receive a positive United States Food and Drug Administration [FDA] Advisory Committee [AdCom] recommendation for a product candidate to treat obesity in 2010, Orexigen Therapeutics, Inc. (OREX) appeared well positioned to receive marketing approval for Contrave® [naltrexone HCl/bupropion HCI]. However, on January 31, 2011, Orexigen and its partner Takeda Pharmaceutical [...]
Drug Development Spotlight: The mTOR’s New Clothes?
November 22, 2010 By Leave a Comment
In 1837, Hans Christian Andersen authored a short tale titled The Emperor’s New Clothes. The main character, so enamored by his appearance and his clothing that he had a different suit for every hour of the day, was swindled by a pair of weavers purporting that they could create clothing from a magical fabric that [...]
Biotech Deal Activity Declines…The Pause that Refreshes?
January 14, 2010 By 1 Comment
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]
Follow MD Becker Partners